Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Study Overview

This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer.

  • The name of the study drug involved in this study is:
  • Zafirlukast

Study Description

A phase 2 study of zafirlukast for the treatment of tumor-marker only relapsed ovarian cancer

  • ClinicalTrials.gov Identifier: NCT04339140
  • Protocol Number: 19-814

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000